The chronic refractory cough market is projected to expand by 2034, driven by rising patient diagnoses, improved awareness, and emerging therapies targeting refractory cough conditions.

Law firm Kaskela Law LLC is investigating Trevi Therapeutics for potential securities law violations or breaches of fiduciary duties, encouraging long-term investors to contact them for more information.

The pulmonary fibrosis market is driven by the increasing prevalence of the disease, especially idiopathic pulmonary fibrosis, among the aging population. Innovations in drug development and diagnostics, favorable reimbursement policies, and greater awareness are fueling market growth. The pipeline appears robust with over 110 active players working on 120+ pipeline drugs.

Trevi Therapeutics (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Trevi Therapeutics (TRVI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Trevi Therapeutics, Inc. (TRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

A more selective small-cap index has consistently outperformed the Russell 2000

Trevi Therapeutics, Inc. (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

The heavy selling pressure might have exhausted for Trevi Therapeutics, Inc. (TRVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Trevi Therapeutics, Inc. (TRVI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Trevi Therapeutics (TRVI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Gainers Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional investors at $2.48 per share. Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares gained 108% to $3.29 after jumping 25% on Monday. BELLUS Health Inc. (NASDAQ: BLU) shares jumped 99.5% to $14.48 after GSK announced it will acquire the company for $14.75 per share in cash, representing an approximate total equity value of $2 billion. SAB Biotherapeutics, Inc. (NASDAQ: SABS) rose 79% to $1.38. The FDA granted Breakthrough Therapy Designation (BTD) to SAB Biotherapeutics SAB-176, an investigational therapy for post-exposure prophylaxis for Type A and Type B influenza illness in high-risk patients, including antiviral resistant strains. HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) gained 57.7% to $4.73 after the company reported key first quarter milestone achievements for drug discovery. Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 55% to $1.84. Super League Gaming, Inc. (NASDAQ: SLGG) surged 39% to $0.5949 after the company and LandVault announced a strategic partnership to provide brands with scalable solutions to bridge the gap between Web2 and Web3. Phio Pharmaceuticals Corp. (NASDAQ: PHIO) rose 38.3% to $8.13. Phio presented preclinical data showing synergy-enhanced in vivo anti-tumor efficacy of PD-1/CTLA-4 dual-targeting INTASYL. Gamida Cell Ltd. (NASDAQ: GMDA) climbed 33% to $1.49 after the U.S. Food and Drug Administration approved Gamida Cell’s allogeneic cell therapy, Omisirge® (omidubicel-onlv). Toro Corp. (NASDAQ: TORO) gained 29.4% to $4.2344. YS Biopharma Co., Ltd. (NASDAQ: YS) gained 26% to $1.99 after the company reported preliminary total revenue of $103 million, representing a year-over-year growth of 30%. Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) shares gained 25% to $4.8212. Trevi Therapeutics, Inc. (NASDAQ: